当前位置：
X-MOL 学术
›
Expert Rev. Vaccines
›
论文详情
Our official English website, www.x-mol.net, welcomes your
feedback! (Note: you will need to create a separate account there.)
Glycoconjugate vaccines: current approaches towards faster vaccine design.
Expert Review of Vaccines ( IF 5.5 ) Pub Date : 2019-08-31 , DOI: 10.1080/14760584.2019.1657012 Francesca Micoli 1 , Linda Del Bino 2 , Renzo Alfini 1 , Filippo Carboni 2 , Maria Rosaria Romano 2 , Roberto Adamo 2
Expert Review of Vaccines ( IF 5.5 ) Pub Date : 2019-08-31 , DOI: 10.1080/14760584.2019.1657012 Francesca Micoli 1 , Linda Del Bino 2 , Renzo Alfini 1 , Filippo Carboni 2 , Maria Rosaria Romano 2 , Roberto Adamo 2
Affiliation
Introduction: Over the last decades, glycoconjugate vaccines have been proven to be a successful strategy to prevent infectious diseases. Many diseases remain to be controlled, especially in developing countries, and emerging antibiotic-resistant bacteria present an alarming public-health threat. The increasing complexity of future vaccines, and the need to accelerate development processes have triggered the development of faster approaches to glycoconjugate vaccines design. Areas covered: This review provides an overview of recent progress in glycoconjugation technologies toward faster vaccine design. Expert opinion: Among the different emerging approaches, glycoengineering has the potential to combine glycan assembly and conjugation to carrier systems (such as proteins or outer membrane vesicles) in one step, resulting in a simplified manufacturing process and fewer analytical controls. Chemical and enzymatic strategies, and their automation can facilitate glycoepitope identification for vaccine design. Other approaches, such as the liposomal encapsulation of polysaccharides, potentially enable fast and easy combination of numerous antigens in the same formulation. Additional progress is envisaged in the near future, and some of these systems still need to be further validated in humans. In parallel, new strategies are needed to accelerate the vaccine development process, including the associated clinical trials, up to vaccine release onto the market.
更新日期：2019-11-01
京公网安备 11010802027423号